HCAT Stock Analysis: Buy, Sell, or Hold?
HCAT - Health Catalyst, Inc Common Stock
$1.18
0.08 (7.27%)
▲
5d:
-2.48%
30d:
-27.16%
90d:
-51.24%
BUY
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 06, 2026
Get Alerted When HCAT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: HCAT shows positive signals but monitor for confirmation. Market pricing in 6.8% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: HCAT shows positive signals but monitor for confirmation. Market pricing in 6.8% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: HCAT is currently trading at $1.18, which is considered oversold relative to its 30-day fair value range of $1.21 to $1.86. From a valuation perspective, the stock is trading at a premium (Forward PE: 7.4) compared to its historical average (6.1). At these levels, the market is pricing in 6.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, HCAT is in a strong downtrend. Immediate support is located at $1.04, while resistance sits at $1.29. The stock is showing strong short-term momentum, up 7.3% recently.
Market Sentiment: HCAT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $1.96 (+66.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HCAT is in a strong downtrend. Immediate support is located at $1.04, while resistance sits at $1.29. The stock is showing strong short-term momentum, up 7.3% recently.
Market Sentiment: HCAT has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $1.96 (+66.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.21 -
$1.86
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.3%)
- BULLISH: Trading 66.5% below Wall St target ($1.96)
- NEUTRAL: Trading at premium valuation - market expects 6.8% growth which is achievable
Fair Price Analysis
30-Day Fair Range
$1.21 -
$1.86
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.04
Resistance Level
$1.29
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.44
Wall Street Target
$1.96
(+66.5%)
Revenue Growth (YoY)
-6.2%
Profit Margin
-57.2%
Valuation Premium vs History
+6.8% premium
PE vs Historical
7.4 vs 6.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.8%
(market-implied from PE analysis)
1-Year Target
$1.26
(+7%)
2-Year Target
$1.35
(+14%)
3-Year Target
$1.44
(+22%)
3-Yr Target (if PE normalizes)
(PE: 7→6)
PE COMPRESSION
$1.18
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 20.6%)
$6.22
(+427%)
Base:
(SPY PE: 7.4, Growth: 20.6%)
$2.07
(+76%)
Bear:
(PE: 6.1, Growth: 20.6%)
$1.70
(+44%)
Share & Embed Analysis
Last updated: March 30, 2026 5:55 PM ET
Data refreshes hourly during market hours. Next update: 6:55 PM
Data refreshes hourly during market hours. Next update: 6:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HCAT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Benjamin Landry
SELL
27425 shares
2025-12-05
Julie Larson-Green
SELL
47997 shares
2025-12-04
Top Rated Health Information Services Stocks
Top-rated stocks in Health Information Services by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VEEV
Veeva Systems Inc Class A |
BUY
32 analysts |
$271 | 50 HOLD |
|
PRVA
Privia Health Group Inc |
STRONG BUY
21 analysts |
$32 | 54 HOLD |
|
GEHC
GE HealthCare Technologi… |
STRONG BUY
21 analysts |
$90 | 59 HOLD |
|
PHR
Phreesia Inc |
STRONG BUY
15 analysts |
$28 | 58 HOLD |
|
HQY
HealthEquity Inc |
STRONG BUY
14 analysts |
$112 | 61 BUY |
Advanced HCAT Option Strategies
Professional options setups generated by AI based on today's HCAT price and gamma walls.
